circadin™ prolonged release tablets 2mg
dksh singapore pte. ltd. - melatonin - tablet, extended release - 2 mg - melatonin 2 mg
hetlioz
vanda pharmaceuticals netherlands b.v. - tasimelteon - sleep disorders, circadian rhythm - psycholeptics - hetlioz is indicated for the treatment of non-24-hour sleep-wake disorder (non-24) in totally blind adults.,
circadin
neurim pharmaceuticals (1991) ltd, israel - melatonin - tablets prolonged release - melatonin 2 mg - melatonin - melatonin - short-term treatment for primary insomnia characterized by poor quality of sleep in patients who are aged 55 or over.
circadin
rad neurim pharmaceuticals eec sarl - melatonin - sleep initiation and maintenance disorders - psycholeptics - circadin is indicated as monotherapy for the short-term treatment of primary insomnia characterised by poor quality of sleep in patients who are aged 55 or over.
circadin 2mg modified-release tablets
flynn pharma ltd - melatonin - modified-release tablet - 2mg
slenyto
rad neurim pharmaceuticals eec sarl - melatonin - sleep initiation and maintenance disorders; autistic disorder - psycholeptics - slenyto is indicated for the treatment of insomnia in children and adolescents aged 2-18 with autism spectrum disorder (asd) and / or smith-magenis syndrome, where sleep hygiene measures have been insufficient.
melatonin pharma nord 3 mg film-coated tablets
pharma nord aps - melatonin - film-coated tablet - 3 milligram(s) - melatonin
circadin
neurim pharmaceuticals (1991) ltd, israel - melatonin - tablets prolonged release - melatonin 2 mg - melatonin - short-term treatment for primary insomnia characterized by poor quality of sleep in patients who are aged 55 or over.
slenyto 1 mg
neurim pharmaceuticals (1991) ltd, israel - melatonin - tablets prolonged release - melatonin 1 mg - melatonin - slenyto is indicated for the treatment of insomnia in children and adolescents aged 2-18 with autism spectrum disorder (asd) and/or smith-magenis syndrome, where sleep hygiene measures have been insufficient.
slenyto 5 mg
neurim pharmaceuticals (1991) ltd, israel - melatonin - tablets prolonged release - melatonin 5 mg - melatonin - slenyto is indicated for the treatment of insomnia in children and adolescents aged 2-18 with autism spectrum disorder (asd) and/or smith-magenis syndrome, where sleep hygiene measures have been insufficient.